By Christy Santhosh Feb 20 (Reuters) – Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez is a one-time therapy that was approved in the U.S. last year, for the treatment of adults with moderate to severe hemophilia…